{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:38:20Z","timestamp":1758044300804,"version":"3.44.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Nirmatrelvir\/ritonavir is licensed for the treatment of mild-to-moderate coronavirus disease (COVID-19) in patients at an increased risk of progression to severe disease. However, data on the real-world plasma exposure to nirmatrelvir\/ritonavir remain limited, particularly in Chinese patients. This study aimed to assess the nirmatrelvir\/ritonavir trough concentration (C<jats:sub>trough<\/jats:sub>) and identify its critical factors in hospitalized Chinese patients treated with nirmatrelvir\/ritonavir 300 mg\/100 mg twice daily over a 5-day course.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A high-performance liquid chromatography-tandem mass spectrometry assay was developed and validated to measure the nirmatrelvir\/ritonavir C<jats:sub>trough<\/jats:sub>. Correlation analyses were performed to identify the variables influencing nirmatrelvir\/ritonavir C<jats:sub>trough<\/jats:sub>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among the 110 patients, 100% had plasma concentrations above the antiviral in vitro 90% effective concentration. The median C<jats:sub>trough<\/jats:sub> of nirmatrelvir was 4.55 mcg\/mL (15.6\u00d7 90% effective concentration), ranging from 0.65 to 12.44 mcg\/mL. Nirmatrelvir C<jats:sub>trough<\/jats:sub> in normal and mild renal impairment cohorts were comparable (4.09 \u00b1 1.97 mcg\/mL and 4.57 \u00b1 2.21 mcg\/mL) but significantly increased in the moderate renal impairment cohort (6.41 \u00b1 2.31 mcg\/mL). Sex, age, and obesity were not significantly associated with nirmatrelvir exposure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Nirmatrelvir C<jats:sub>trough<\/jats:sub> was high in Chinese patients with COVID-19, and therapeutic drug monitoring should not be routinely recommended, except in patients with renal impairment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001305","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T08:01:00Z","timestamp":1738224060000},"page":"619-624","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world Plasma Exposure of Nirmatrelvir\/Ritonavir in Chinese Hospitalized Patients With COVID-19: A Multicenter Retrospective Study"],"prefix":"10.1097","volume":"47","author":[{"given":"Zhiyuan","family":"Ma","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China;"},{"name":"Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Hangzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengru","family":"Bai","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China;"},{"name":"Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Hangzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuying","family":"Shen","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China;"},{"name":"Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Hangzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junshan","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China;"},{"name":"Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Dong","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China;"},{"name":"Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Hangzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayun","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhejiang Hospital, Hangzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongchen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Maternal and Child Health Hospital of Chun'an, Hangzhou, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[{"name":"Shanghai AB Sciex Analytical Instrument Trading Co, Ltd, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[{"name":"Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Hangzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nengming","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China;"},{"name":"Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Hangzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmei","family":"Xia","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China;"},{"name":"Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Hangzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"R1-20250912","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40262-023-01339-y","article-title":"A comprehensive review of the clinical pharmacokinetics, pharmacodynamics, and drug interactions of nirmatrelvir\/ritonavir","volume":"63","author":"Gerhart","year":"2024","journal-title":"Clin Pharmacokinet."},{"key":"R2-20250912","doi-asserted-by":"crossref","first-page":"n1648","DOI":"10.1136\/bmj.n1648","article-title":"Long covid-mechanisms, risk factors, and management","volume":"374","author":"Crook","year":"2021","journal-title":"BMJ"},{"key":"R3-20250912","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"R4-20250912","doi-asserted-by":"crossref","first-page":"e28756","DOI":"10.1002\/jmv.28756","article-title":"Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a retrospective cohort study","volume":"95","author":"Deng","year":"2023","journal-title":"J Med Virol."},{"key":"R5-20250912","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpt.2603","article-title":"Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir","volume":"112","author":"Singh","year":"2022","journal-title":"Clin Pharmacol Ther."},{"key":"R7-20250912","doi-asserted-by":"crossref","first-page":"1161897","DOI":"10.3389\/fphar.2023.1161897","article-title":"Nirmatrelvir\/Ritonavir for hemodialysis patients with COVID-19","volume":"14","author":"Lu","year":"2023","journal-title":"Front Pharmacol."},{"key":"R8-20250912","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2215\/CJN.05270522","article-title":"Prescribing nirmatrelvir\/ritonavir for COVID-19 in advanced CKD","volume":"17","author":"Hiremath","year":"2022","journal-title":"Clin J Am Soc Nephrol."},{"key":"R9-20250912","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cpt.2688","article-title":"Pharmacokinetics of oral nirmatrelvir\/ritonavir, a protease inhibitor for treatment of COVID-19, in subjects with renal impairment","volume":"112","author":"Toussi","year":"2022","journal-title":"Clin Pharmacol Ther."},{"key":"R10-20250912","first-page":"106997","article-title":"High concentrations of nirmatrelvir\/ritonavir in critically ill patients receiving continuous renal replacement therapy","author":"Rong","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"R11-20250912","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jcph.2353","article-title":"Effect of hepatic impairment on the pharmacokinetics of nirmatrelvir\/ritonavir, the first oral protease inhibitor for the treatment of COVID-19","volume":"64","author":"Singh","year":"2024","journal-title":"J Clin Pharmacol."},{"key":"R12-20250912","doi-asserted-by":"crossref","first-page":"e5456","DOI":"10.1002\/bmc.5456","article-title":"Simultaneous determination of nirmatrelvir and ritonavir in human plasma using LC-MS\/MS and its pharmacokinetic application in healthy Chinese volunteers","volume":"36","author":"Liu","year":"2022","journal-title":"Biomed Chromatogr."},{"key":"R13-20250912","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"key":"R14-20250912","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12916-020-01726-3","article-title":"COVID-19 length of hospital stay: a systematic review and data synthesis","volume":"18","author":"Rees","year":"2020","journal-title":"BMC Med."},{"key":"R15-20250912","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"R16-20250912","doi-asserted-by":"crossref","first-page":"115796","DOI":"10.1016\/j.jpba.2023.115796","article-title":"Simultaneous quantification of nirmatrelvir\/ritonavir in human serum by LC-HRMS","volume":"237","author":"Zhao","year":"2024","journal-title":"J Pharm Biomed Anal."},{"key":"R17-20250912","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.farma.2023.02.003","article-title":"Paradoxical interaction between nirmatrelvir\/ritonavir and voriconazole in a patient with COVID-19","volume":"47","author":"Bayo","year":"2023","journal-title":"Farm Hosp."},{"key":"R18-20250912","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/cid\/ciad159","article-title":"Complexity interactions between nirmatrelvir\/ritonavir and voriconazole in patients with coronavirus disease 2019","volume":"76","author":"Wang","year":"2023","journal-title":"Clin Infect Dis."},{"key":"R19-20250912","doi-asserted-by":"crossref","first-page":"106535","DOI":"10.1016\/j.ejps.2023.106535","article-title":"Population pharmacokinetic modeling and simulation for nirmatrelvir exposure assessment in Chinese older patients with COVID-19 infection","volume":"189","author":"Qu","year":"2023","journal-title":"Eur J Pharm Sci."},{"key":"R20-20250912","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/cpt.2683","article-title":"Metabolism and excretion of nirmatrelvir in humans using quantitative fluorine nuclear magnetic resonance spectroscopy: a novel approach for accelerating drug development","volume":"112","author":"Singh","year":"2022","journal-title":"Clin Pharmacol Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:01:58Z","timestamp":1757678518000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001305","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"2024-09-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}